{"entity":{"id":"nct06780839","kind":"trial","name":"Adjuvant Treatment of ALK-positive Non-small Cell Lung Cancer with Ensartinib Guided by MRD","aka":[],"tldr":"A phase 2 trial of ensartinib in lung cancer, run by Peking University Cancer Hospital & Institute, not yet recruiting.","summary":"Adjuvant Treatment of ALK-positive Non-small Cell Lung Cancer with Ensartinib Guided by MRD is a phase 2, interventional study registered as NCT06780839 by Peking University Cancer Hospital & Institute, with a registry enrolment figure of 70 participants, started 2025-01-15 and due to reach its primary completion in 2029-01-15. Interventions recorded: Ensartinib. Conditions listed: NSCLC, Stage I, II, IIIA, IIIB. Primary outcome: DFS. Lung eligibility wording from the registry: \"Histologically confirmed primary non-small cell lung cancer;\". Sites: China. No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-25","links":[{"label":"ClinicalTrials.gov NCT06780839","url":"https://clinicaltrials.gov/study/NCT06780839"}],"tags":["ctgov-ingest","lung-deep-dive"],"related":[],"cancers":["alk-positive-nsclc","resectable-nsclc"],"sections":[],"technologies":["kinase-inhibitors"],"targets":[],"drugs":["ensartinib"],"companies":["betta"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06780839","phase":"2","setting":"Postoperative Adjuvant Treatment of ALK-positive Non-small Cell Lung Cancer with Ensartinib Guided by MRD: a Single-arm, Multicenter Study","sponsor":"Peking University Cancer Hospital & Institute","participation":[{"nct":"NCT06780839","source":"https://clinicaltrials.gov/study/NCT06780839","fetchedAt":"2026-10-07T16:55:03.017Z","studySha256":"a5789d42bb6e8f388d79c0a7f4c5487bbf9c3cb83c3a5abecb2605f6f64be593","overallStatus":"NOT_YET_RECRUITING","lastUpdatePosted":"2025-01-17","leadSponsor":"Peking University Cancer Hospital & Institute","collaboratorCount":1,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":70,"enrolmentType":"ESTIMATED","siteCount":1,"recruitingSiteCount":0,"countries":["China"]}],"started":"2025-01-15","startedType":"estimated","enrolled":70,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06780839/","neighbours":{"cancer":[{"id":"alk-positive-nsclc","kind":"cancer","name":"ALK-positive non-small-cell lung cancer","route":"/cancers/alk-positive-nsclc/"},{"id":"resectable-nsclc","kind":"cancer","name":"Resectable stage I to III non-small-cell lung cancer","route":"/cancers/resectable-nsclc/"}],"technology":[{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"drug":[{"id":"ensartinib","kind":"drug","name":"Ensartinib","route":"/drugs/ensartinib/"}],"company":[{"id":"betta","kind":"company","name":"Betta Pharmaceuticals","route":"/companies/betta/"}],"term":[{"id":"lung-trials-open-today","kind":"term","name":"Lung cancer trials open today (registry snapshot)","route":"/terms/lung-trials-open-today/"}]}}